Genetic reduction of the E3 ubiquitin ligase element, SKP1A and environmental manipulation to emulate cardinal features of Parkinson's disease

Parkinsonism and Related Disorders

Volumn 18, Issue SUPPL. 1, 2012, Pages

  Mandel, Silvia A ^a   Fishman Jacob, Tali ^a   Youdim, Moussa B H ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Disease model; Dopaminergic markers; SCF E3 complex; Short hairpin RNA lentiviruses; Sporadic Parkinson's disease

Indexed keywords

ALDEHYDE DEHYDROGENASE; ALDEHYDE DEHYDROGENASE ISOENZYME 1; DOPAMINE; LENTIVIRUS VECTOR; SHORT HAIRPIN RNA; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN INFECTION; CELL CYCLE; CELL DIFFERENTIATION; CLINICAL FEATURE; DOPAMINERGIC NERVE CELL; ECOLOGICAL GENETICS; ENVIRONMENTAL FACTOR; GENE EXPRESSION; GENE INTERACTION; GENE PRODUCT; HEREDITY; LEWY BODY; MOUSE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SKP1A GENE; SUBSTANTIA NIGRA;

EID: 84858667409     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/s1353-8020(11)70055-4     Document Type: Article

References (20)

1. Gao HM, Hong JS. Gene-environment interactions: key to unraveling themystery of Parkinson's disease. Progr Neurobiol 2011;94:1-19.
2. Vance JM, Ali S, Bradley WG, Singer C, Di Monte DA. Gene-environment interactions in Parkinson's disease and other forms of parkinsonism. Neurotoxicology 2010;31:598-602.
3. Dick FD, De Palma G, Ahmadi A, Scott NW, Prescott GJ, Bennett J, et al. Environmental risk factors for Parkinson's disease and parkinsonism: the Geoparkinson study. Occup Environ Med 2007;64:666-72.
4. Singh M, Khan AJ, Shah PP, Shukla R, Khanna VK, Parmar D. Polymorphism in environment responsive genes and association with Parkinson disease. Mol Cell Biochem 2008;312:131-8.
5. Dauer W, Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003;39:889-909.
6. Mandel S, Grunblatt E, Riederer P, Gerlach M, Levites Y, Youdim MB. Neuroprotective strategies in Parkinson's disease: an update on progress. CNS Drugs 2003;17:729-62.
7. Zhou C, Huang Y, Przedborski S. Oxidative stress in Parkinson's disease: a mechanism of pathogenic and therapeutic significance. Ann NY Acad Sci 2008;1147:93-104.
8. Mandel S, Morelli M, Halperin I, Korczyn AD. Biomarkers for prediction and targeted prevention of Alzheimer's and Parkinson's diseases: evaluation of drug clinical efficacy. EPMA J 2010;1(2):273-92.
9. Grunblatt E, Mandel S, Jacob-Hirsch J, Zeligson S, Amariglo N, Rechavi G, et al. Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes. J Neural Transm 2004;111:1543-73.
10. Mandel SA, Fishman T, Youdim MB. Gene and protein signatures in sporadic Parkinson's disease and a novel genetic model of PD. Parkinsonism Relat Disord 2007;13(Suppl 3):S242-7.
11. Fishman-Jacob T, Reznichenko L, Youdim MB, Mandel SA. A sporadic Parkinson's disease model via silencing of the ubiquitin-proteasome/E3-ligase component, SKP1A. J Biol Chem 2009;284(47):32835-45.
12. Zheng N, Schulman BA, Song L, Miller JJ, Jeffrey PD, Wang P, et al. Structure of the Cul1-Rbx1-Skp1-F boxSkp2 SCF ubiquitin ligase complex. Nature 2002;416: 703-9.
13. Di Fonzo A, Dekker MC, Montagna P, Baruzzi A, Yonova EH, Correia Guedes L, et al. FBXO7 mutations cause autosomal recessive, early-onset parkinsonianpyramidal syndrome. Neurology 2009;72:240-5.
14. Nelson RF, Glenn KA, Zhang Y, Wen H, Knutson T, Gouvion CM, et al. Selective cochlear degeneration in mice lacking the F-box protein, Fbx2, a glycoproteinspecific ubiquitin ligase subunit. J Neurosci 2007;27:5163-71.
15. Jenner P. Oxidative stress in Parkinson's disease. Ann Neurol 2003;53(Suppl 3): S26-36; discussion
16. Barzilai A, Melamed E. Molecular mechanisms of selective dopaminergic neuronal death in Parkinson's disease. Trends Mol Med 2003;9:126-32.
17. Fishman-Jacob T, Youdim MB, Mandel SA. Silencing/overexpressing selected genes as a model of sporadic Parkinson's disease. Neurodegener Dis 2010;7: 108-11.
18. Boger HA, Granholm AC, McGinty JF, Middaugh LD. A dual-hit animal model for age-related parkinsonism. Prog Neurobiol 2010;90:217-29.
19. Manning-Bog AB, Langston JW. Model fusion, the next phase in developing animal models for Parkinson's disease. Neurotox Res 2007;11:219-40.
20. Frank-Cannon TC, Tran T, Ruhn KA, Martinez TN, Hong J, Marvin M, et al. Parkin deficiency increases vulnerability to inflammation-related nigral degeneration. J Neurosci 2008;28:10825-34.